Gilead Sciences has announced a strategic partnership with Genesis Therapeutics, aimed at using AI to discover and develop ...

Genesis Therapeutics’ shiny AI drug discovery platform GEMS is catching on, having now caught the eye of Gilead Sciences. | ...

Gilead Sciences has formed a partnership with PANTHERx Rare to distribute LIVDELZI, a treatment for adults with primary biliary cholangitis (PBC). The collaboration aims to provide patients with ...

Avenzo Therapeutics announced a trial partnership and supply agreement with Gilead Sciences to assess a combination regimen ...

Gilead Sciences has been looking for a win for Trodelvy after two ... He also pointed to Gilead’s partnership with Arcus ...

Gilead Sciences has made another foray into the ... The platform has also attracted partnerships from other pharma groups, including AbbVie, Merck & Co and Bristol-Myers Squibb/Celgene.

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Gilead Sciences and Genesis Therapeutics have entered a strategic collaboration to discover and develop novel small molecule ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...

The ball, supported by presenting sponsor Gilead Sciences, will take place at the Beverly Hills Hotel on Sept. 26. In ...